Human papillomavirus early proteins E6 and E7 (HPV E6/E7)

Human papillomavirus (HPV) early proteins E6 and E7 are the primary oncoproteins responsible for the development and maintenance of HPV-associated malignancies. E6 targets the p53 tumor suppressor for proteasomal degradation, while E7 binds and inactivates the retinoblastoma protein (pRb), collectively leading to cell cycle dysregulation and the inhibition of apoptosis (Source: UniProt P03126, P03129). In the context of therapeutic vaccines, these proteins serve as non-self antigens that are constitutively expressed in precancerous and cancerous cells, making them ideal targets for immunotherapy. Vaccine-encoded transgenes, delivered via DNA, mRNA, or viral vectors, instruct host cells to produce these antigens, which are then presented to the immune system to prime a robust T-cell response (Source: PubMed, PMID: 32810124). This indirect targeting strategy aims to eliminate HPV-infected cells by leveraging the host's cellular immunity, specifically cytotoxic T-lymphocytes, to recognize E6 and E7 epitopes presented on MHC class I molecules (Source: NIH, National Cancer Institute). Clinical development focuses on treating high-grade cervical dysplasia and various HPV-positive solid tumors where traditional prophylactic vaccines are ineffective (Source: Inovio Pharmaceuticals, VGX-3100; ISA Pharmaceuticals, ISA101).

Other names

HPV E6HPV E7Human papillomavirus oncoproteinsHigh-risk HPV E6/E7HPV16 E6/E7HPV18 E6/E7

Induction of antigen-specific CD8+ cytotoxic T-lymphocyte and CD4+ helper T-cell responses against cells expressing E6 and E7 oncoproteins via vaccine-encoded transgenes.